This drug offers 99.9% protection against HIV, but there's a catch
The US FDA has approved lenacapavir, the first twice-yearly injection for HIV prevention, which provides near-complete protection. However, its cost — ₹24 lakh per shot — may make it inaccessible in India
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
A new HIV drug promises 99.9% protection. But it's making Indian health activists wary; Why?
The US Food and Drug Administration (FDA) has approved lenacapavir, a new injectable drug that claims to offer 99.9% protection against HIV. But concerns are being raised in India over its affordability and accessibility, particularly through the public healthcare system. The injection costs around ₹24 lakh ($28,218) for two doses administered six months apart. Lenacapavir belongs to the class of HIV prevention drugs known as pre-exposure prophylaxis (PrEP). However, India's National AIDS Control Organisation (NACO) has not included PrEP in its public programmes so far. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hanoi: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Undo He added that NACO had made it mandatory for its counselling centres to provide information on PrEP a couple of years ago. He also expressed concern that 75% of the 88% people diagnosed with HIV in Mumbai in 2023–24 were from the 15–49 age group. PrEP, however, remains available only in the private sector. Experts call for government action, tiered pricing PrEP has existed for over a decade and is widely used in developed countries. In India, public health discussions around PrEP only began recently. Live Events A doctor from a government hospital said, "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since." Dr Ishwar Gilada of the People's Health Organisation (India) said, "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years." According to him, sexually transmitted infections have been rising in Mumbai. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," he said. He suggested a three-tier pricing structure: full price for those who can afford it, subsidised pricing for some, and free access for those unable to pay. NACO officials were not available for comment. India has also not approved HIV self-testing kits. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. A senior doctor suggested that similar fears may be behind the delay in rolling out PrEP publicly, as officials worry it might encourage risky behaviour. Hope for lower-cost versions as UNAIDS urges price drop Bala from Bombay Gay called lenacapavir a "monumental milestone forward in HIV treatment and prevention," but added that the current price point makes it inaccessible in India. "So, we have to wait and see if prices will come down over time," he said. Dr Gilada expressed hope that Indian manufacturers licensed by Gilead Sciences might eventually offer the injection at less than $100 per year. "India can do it," he said. UNAIDS, in a recent statement, urged Gilead Lifesciences to reduce the price of the new drug to improve global access.
Time of India
5 hours ago
- Time of India
This drug offers 99.9% protection against HIV, but there's a catch
The US FDA has approved lenacapavir, the first twice-yearly injection for HIV prevention, which provides near-complete protection. However, its cost — ₹24 lakh per shot — may make it inaccessible in India
Time of India
17 hours ago
- Time of India
Drug offers 99.9% HIV shield, but Indians will have to wait
Mumbai: A new drug promising 99.9% protection against HIV received approval from the US Food & Drug Administration (FDA) a few days ago, but the city's HIV rights activists are sceptical about its practical impact in India. The main concern stems from the new injectable drug lenacapavir's substantial cost of Rs 24 lakh ($28,218) per person for two injections taken six months apart. Also, NACO (National AIDS Control Organisation) has not fully embraced PrEP (pre-exposure prophylaxis) medications, the category to which lenacapavir belongs. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. A couple of years ago, NACO made it mandatory for its counselling centres to disburse information on PrEP. He is alarmed because 75% of the 88% diagnosed with HIV in Mumbai between 2023-24 were in the 15-49 age group that is classified as young. PrEP is available for those seeking treatment in the private sector. PrEP, as a method to prevent HIV transmission before a risky exposure, has been around for almost 12 years. It was widely accepted in developed countries, but India's public health machinery never mentioned it until a few years ago. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since," said a doctor with a public hospital. Dr Ishwar Gilada of the People's Health Organisation (India) said PrEP is the lesser evil compared to HIV transmission. "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years," he added. The problem is more pronounced in Mumbai, he said, where the number of people with sexually transmitted diseases has been rising. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," said Dr Gilada. PrEP would be the solution, according to him. The govt could adopt a three-tier payment system for PrEP: Charge full cost from those who can afford it, subsidy for some, and free for those who cannot afford medications. Despite efforts, NACO officials were not available for comment. PrEP is not the only HIV-related policy that the govt hasn't acted on. Self-testing HIV kits, for instance, are not allowed in India. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. The same logic is possibly behind the delay with introducing PrEP in the public health system, said a senior doctor, as a section of public health officials fear that giving PrEP would seem like a licence for risky behaviour. However, there is hope that lenacapavir would be available in India sooner rather than later. Bala of Bombay Gay said lenacapavir is a "monumental milestone forward in HIV treatment and prevention," but its pricing makes it inaccessible to Indian patients. "So, we have to wait and see if prices will come down over time," he added. Dr Gilada is positive Indian generic pharma companies licensed by Gilead Sciences can bring lenacapavir injections at below $100 per annum cost and may be rolled out soon. "India can do it," he said. In a statement released a couple of days ago, UNAIDS urged Gilead Lifesciences to drop the price of the new HIV prevention shot.
